Institut National de la Santé et de la Recherche Médicale, Le Kremlin Bicêtre, France.
Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
J Clin Endocrinol Metab. 2019 May 1;104(5):1777-1787. doi: 10.1210/jc.2018-01504.
Besides GNAS gene mutations, the molecular pathogenesis of somatotroph adenomas responsible for gigantism and acromegaly remains elusive.
To investigate alternative driver events in somatotroph tumorigenesis, focusing on a subgroup of acromegalic patients with a paradoxical increase in growth hormone (GH) secretion after oral glucose, resulting from ectopic glucose-dependent insulinotropic polypeptide receptor (GIPR) expression in their somatotropinomas.
DESIGN, SETTING, AND PATIENTS: We performed combined molecular analyses, including array-comparative genomic hybridization, RNA/DNA fluorescence in situ hybridization, and RRBS DNA methylation analysis on 41 somatotropinoma samples from 38 patients with acromegaly and three sporadic giants. Ten patients displayed paradoxical GH responses to oral glucose.
GIPR expression was detected in 13 samples (32%), including all 10 samples from patients with paradoxical GH responses. All GIPR-expressing somatotropinomas were negative for GNAS mutations. GIPR expression occurred through transcriptional activation of a single allele of the GIPR gene in all GIPR-expressing samples, except in two tetraploid samples, where expression occurred from two alleles per nucleus. In addition to extensive 19q duplications, we detected in four samples GIPR locus microamplifications in a certain proportion of nuclei. We identified an overall hypermethylator phenotype in GIPR-expressing samples compared with GNAS-mutated adenomas. In particular, we observed hypermethylation in the GIPR gene body, likely driving its ectopic expression.
We describe a distinct molecular subclass of somatotropinomas, clinically revealed by a paradoxical increase of GH to oral glucose related to pituitary GIPR expression. This ectopic GIPR expression occurred through hypomorphic transcriptional activation and is likely driven by GIPR gene microamplifications and DNA methylation abnormalities.
除了 GNAS 基因突变外,导致巨人症和肢端肥大症的生长激素腺瘤的分子发病机制仍不清楚。
研究生长激素腺瘤发生的其他驱动事件,重点关注一组肢端肥大症患者,他们的生长抑素瘤中存在异位葡萄糖依赖性胰岛素释放多肽受体 (GIPR) 表达,导致口服葡萄糖后 GH 分泌出现反常增加。
设计、地点和患者:我们对来自 38 例肢端肥大症患者和 3 例散发性巨人症患者的 41 例生长激素腺瘤样本进行了联合分子分析,包括阵列比较基因组杂交、RNA/DNA 荧光原位杂交和 RRBS DNA 甲基化分析。10 例患者表现出口服葡萄糖后 GH 反应反常。
在 13 例样本(32%)中检测到 GIPR 表达,包括所有 10 例 GH 反应反常的患者样本。所有 GIPR 表达的生长激素腺瘤均无 GNAS 突变。在所有 GIPR 表达的样本中,除了两个四倍体样本外,GIPR 基因的一个等位基因通过转录激活来表达 GIPR,在每个核中表达两个等位基因。除了广泛的 19q 重复外,我们在四个样本中还检测到 GIPR 基因座微扩增在一定比例的核中。与 GNAS 突变的腺瘤相比,我们发现 GIPR 表达的样本中存在整体高甲基化表型。特别是,我们观察到 GIPR 基因体的甲基化增加,可能驱动其异位表达。
我们描述了一个独特的生长激素腺瘤分子亚类,临床上表现为口服葡萄糖后 GH 增加反常,与垂体 GIPR 表达有关。这种异位的 GIPR 表达是通过低功能转录激活发生的,可能是由 GIPR 基因微扩增和 DNA 甲基化异常驱动的。